Video

Dr. Richardson on the Use of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

CDK4/6 inhibitors have had a dramatic impact on the management of patients with metastatic HR-positive, HER2- breast cancer. Currently, all 3 agents

Related Videos
Jorge E. Cortes, MD
Nicolas Girard, MD
Sunil Adige, MD
Minoo Battiwalla, MD, MS
Samuel J. Klempner, MD
Jill Corre, PharmD, PhD
Chad Tang, MD
Grzegorz S. Nowakowski, MD, consultant, Division of Hematology, Department of Internal Medicine, enterprise deputy director, Clinical Research, professor, oncology, medicine, Mayo Clinic Comprehensive Cancer Center
Leo I. Gordon, MD
Terence W. Friedlander, MD